Ticker brief
IONS
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
15
authors 14d
10
crowd 14d
-0.9σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 50% mid · 51 pctile own 1y | HV n/a |
| Skew — 25Δ RR 30d | -0.039 59 pctile own 1y | balanced vs own range |
| OI alarm | quiet | last alarm 2026-06-30 (z=7.8) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-16 → 2026-08-28 · now -0.34 (−1 bearish … +1 bullish)
Who spoke10
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @BiopharmIQ | B | · | 3 | -0.15 |
| @PSInvestor | B | -1.48 | 2 | +0.25 |
| @Markadiusz45 | C | +1.18 | 2 | +0.20 |
| @adamfeuerstein | A | +1.41 | 2 | -0.30 |
| @kkernttb | C | -2.19 | 1 | +0.40 |
| @OracleNYSE | C | -0.08 | 1 | +0.45 |
| @PersimmonTI | A | -0.57 | 1 | +0.00 |
| @OptionsFlowBoss | C | · | 1 | +0.45 |
| @TheNewMoney_app | C | · | 1 | +0.45 |
| @fwpharma | B | +0.98 | 1 | -0.15 |
Recent signals15of 15 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @fwpharma | -0.15 | Reports an AstraZeneca ATTR-CM study miss that raises questions for competing therapies. | · | tweet ↗ |
| 2026-08-28 | @BiopharmIQ | -0.60 | Late-stage eplontersen trial missed its primary endpoint, outweighing positive early-stage data | · | tweet ↗ |
| 2026-08-28 | @adamfeuerstein | -0.25 | Provides subgroup cardiovascular event-rate ratios from a study relevant to four amyloidosis drug companies. | · | tweet ↗ |
| 2026-08-28 | @adamfeuerstein | -0.35 | Reports a failed AstraZeneca heart-disease study and broader concerns for silencer drugs. | · | tweet ↗ |
| 2026-08-24 | @TheNewMoney_app | +0.45 | Reports a $510,000 purchase of IONS $75 calls expiring January 2027. | · | tweet ↗ |
| 2026-08-24 | @OptionsFlowBoss | +0.45 | Detects a bullish call spread in IONS options flow. | · | tweet ↗ |
| 2026-08-23 | @PersimmonTI | +0.00 | Interprets research after NVO's ZEUS failure and proposes Lp(a)-stratified inflammation analysis. | · | tweet ↗ |
| 2026-08-19 | @PSInvestor | +0.30 | Reports ARK Invest's dated buy and sell transactions; output capped at six tickers | · | tweet ↗ |
| 2026-08-19 | @OracleNYSE | +0.45 | Cites Musk's claim that synthetic RNA will cure many diseases, implying optimism for RNA developers. | · | tweet ↗ |
| 2026-08-19 | @Markadiusz45 | +0.15 | Lists neglected RNA-related charts generated by ChatGPT. | · | tweet ↗ |
| 2026-08-19 | @Markadiusz45 | +0.25 | Suggests an emerging RNA-stock season and supplies a multi-name thematic basket. | · | tweet ↗ |
| 2026-08-18 | @PSInvestor | +0.20 | Reports ARK Invest's dated buy and sell transactions; buy-side names retained up to the ticker cap. | · | tweet ↗ |
| 2026-08-18 | @kkernttb | +0.40 | IONS is breaking out of a range | · | tweet ↗ |
| 2026-08-16 | @BiopharmIQ | +0.15 | Quantifies biopharma-focused hedge-fund ownership across three catalyst names. | · | tweet ↗ |
| 2026-08-16 | @BiopharmIQ | +0.00 | Q3 biotech clinical-catalyst watchlist names phases and timing. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.